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Abstract 
Results from several studies indicate that cyclooxygenase-2 (COX-2) is involved ischemic brain 
injury. The purpose of this study was to evaluate the neuroprotective effects of the selective 
COX-2 inhibitor nimesulide on cerebral infarction and neurological deficits in a standardized 
model of transient focal cerebral ischemia in rats. Three doses of nimesulide (3, 6 and 12 mg/kg; 
i.p.) or vehicle were administered immediately after stroke and additional doses were given at 6, 
12, 24, 36 and 48 h after ischemia. In other set of experiments, the effect of nimesulide was 
studied in a situation in which its first administration was delayed for 3 to 24 h after ischemia. 
Total, cortical and subcortical infarct volumes and functional outcome (assessed by neurological 
deficit score and rotarod performance) were determined 3 days after ischemia. The effect of 
nimesulide on prostaglandin E2 (PGE2) levels in the injured brain was also investigated. 
Nimesulide dose-dependently reduced infarct volume and improved functional recovery when 
compared to vehicle. Of interest is the finding that neuroprotection conferred by nimesulide 
(reduction of infarct size and neurological deficits and improvement of rotarod performance) was 
also observed when treatment was delayed until 24 h after ischemia. Further, administration of 
nimesulide in a delayed treatment paradigm completely abolished PGE2 accumulation in the 
postischemic brain, suggesting that COX-2 inhibition is a promising therapeutic strategy for 
cerebral ischemia to target the late-occurring inflammatory events which amplify initial damage.  
 
Theme: Disorders of the nervous system 
Topic: Ischemia 
Key words: cerebral ischemia; nimesulide; cyclooxygenase-2; functional outcome; stroke; 
neuroprotection 
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1. INTRODUCTION 
 
Stroke is a leading cause of death and disability worldwide. Development of an effective therapeutic 
strategy for stroke has been a priority of neuroscientists for decades. Considerable research efforts have 
been devoted to the development of neuroprotective agents to save neurons from the biochemical and 
metabolic consequences of ischemic brain injury.  
 
Current approaches to treat acute ischemic stroke include thrombolytic therapy (reperfusion), 
neuroprotection, and administration of neurorestorative agents. Intravenous thrombolysis within 3 hours 
after symptoms onset represents the first therapeutical approach that can effectively treat acute ischemic 
stroke [70]. Although adequate treatment should be started as early as possible, most patients still arrive 
at the hospital too late to receive the maximum benefit from this emerging therapy [2]. Despite the 
recently published PROACT II clinical trial, which first demonstrated the efficacy of intra-arterial 
thrombolysis within 6 hours of stroke onset [28], until now, thrombolysis has not been approved for 
intravenous administration >3 hours after stroke onset because the risk of hemorrhage increases with 
time [2,28].   
 
In search of an effective treatment of stroke, numerous studies have been conducted to understand the 
pathophysiological mechanisms that lead to neuronal death. Among the initial events in the ischemic 
cascade are the widespread neuronal depolarization and massive release of glutamate (excitotoxicity) 
leading to calcium influx. Approaches focusing on blocking presynaptic glutamate release, ionotropic 
glutamate receptors, or voltage-sensitive calcium or sodium channels have so far failed to demonstrate a 
proven clinical efficacy [18,23,30].  
 
Other therapeutic strategies for stroke include hypothermia [20,65,81], antioxidants [7,13,14,64], 
blockade of excessive synaptic Zn2+ release [75], antiapoptotic strategies [26,53], administration of 
growth factors [1,40], erythropoietin [67], recombinant human interleukin-1 receptor antagonist [47], 
statins [73], gene therapy [80,81] and approaches involving transfer of new cells, such as stem cells, and 
neuronal precursors cells [1,46,63].   
 
Recent experimental evidences have shown that brain damage occurring after focal cerebral ischemia 
(FCI) develops over a relatively long period of time [34,51]. One of the processes that plays a pivotal role 
in the delayed progression of brain damage is postischemic inflammation [19,34,51]. Cerebral ischemia is 
followed by infiltration of neutrophils in the injured brain, an event initiated by the expression of pro-
inflammatory cytokines, chemokines, and adhesion molecules (for review, see reference 19). In addition, 
the marked expression of inflammation-related enzymes such as inducible nitric oxide synthase (iNOS) 
and cyclooxygenase-2 (COX-2) plays an important role in the secondary events that amplify cerebral 
damage after ischemia.  
 
COX-2 mRNA and protein levels have shown to be significantly increased within neurons and vascular 
cells in both experimental animal models of cerebral ischemia [15,21,38,43,50,51,55,61] and in infarcted 
human brain [35,60]. Moreover, administration of highly selective COX-2 inhibitors has been proven to 
reduce brain damage and prostaglandin accumulation following cerebral ischemia [9-12,50,51]. The 
observations that enhanced COX-2 activity contributes to amplify cerebral injury after stroke offer an 
interesting prospect for targeting the late phase of the damage with COX-2 inhibitors.   
 
In view that most patients with ischemic stroke reach the hospital several hours after the onset of 
symptoms, it is now considered of paramount importance to demonstrate significant neuroprotection after 
delayed administration of a compound. Hence, the aim of the present study was to investigate the 
effectiveness of the selective COX-2 inhibitor nimesulide (N-(4-nitro-2-phenoxyphenyl)-
methanesulfonamide) when treatment started at various intervals after the onset of stroke. Nimesulide is 
Candelario-Jalil et al. 2004                                               Brain Research Vol. 1007, pp. 98-108 (2004) 
 4
a non-steroidal anti-inflammatory drug with potent effects, showing a high affinity and selectivity for COX-
2 [16]. This compound has been widely used for 20 years to treat inflammatory conditions and fever and 
readily crosses the blood-brain barrier [16,69].  
 
This study was prompted by our previous results with this COX-2 inhibitor in transient global cerebral 
ischemia [9,12] and in a model of in vivo kainate-induced excitotoxicity [8]. The present study used a 
standardized model of middle cerebral artery occlusion (MCAO) induced by an intraluminal suture and 
several measures of nimesulide’s efficacy were considered (infarct volume, neurological deficits, motor 
impairment using the rotarod test, and accumulation of PGE2 in infarcted cerebral cortex). We found that 
nimesulide potently protects against neuronal damage and improves functional outcome even when 
treatment is delayed up to 24 h after the onset of FCI. 
 
 
2. MATERIALS AND METHODS 
 
2.1. Animals 
All the experimental procedures were performed strictly according to the regulations of the Havana 
University’s animal ethical committee and the guidelines of the National Institutes of Health (Bethesda, 
MD, USA) for the care and use of laboratory animals for experimental procedures. Our institutional 
animal care and use committee approved the experimental protocol (No. 03/113). Male Sprague-Dawley 
rats (CENPALAB, Havana, Cuba) weighing 270-320 g at the time of surgery were used in the present 
study. The animals were quarantined for at least 7 days before the experiment. Animals were housed in 
groups in a room whose environment was maintained at 21-25 ºC, 45-50 % humidity and 12-h light/dark 
cycle. They had free access to pellet chow and water.  
 
2.2. Procedures for transient middle cerebral artery occlusion (MCAO)  
Rats were anesthetized with chloral hydrate (300 mg/kg body weight, i.p.). Once  surgical levels of 
anesthesia were attained (assessed by absence of hind leg withdrawal to pinch), ischemia was induced 
by using an occluding intraluminal suture [41,59,80]. Briefly, the right common carotid artery (CCA) and 
the external carotid artery (ECA) were exposed by a ventral midline neck incision and ligated with a 3-0 
silk suture. The pterygopalatine branch of the internal carotid artery was clipped to prevent incorrect 
insertion of the occluder filament. Arteriotomy was performed in the CCA approximately 3 mm proximal to 
the bifurcation and a 3-0 monofilament nylon suture (Shenzhen Runch Industrial Corp., China), whose tip 
had been rounded by being heated near a flame, was introduced into the internal carotid artery (ICA) until 
a mild resistance was felt. Mild resistance to this advancement indicated that the intraluminal occluder 
had entered the anterior cerebral artery (ACA) and occluded the origin of the ACA, the middle cerebral 
artery (MCA) and posterior communicating arteries. The occluding suture was kept in place for 1 h. At the 
end of the ischemic period, the suture was gently retracted to allow reperfusion of the ischemic region. 
The incision was closed and animals were allowed to recover from anesthesia and to eat and drink freely. 
Rectal temperature was maintained at 37±0.5 °C with a heat lamp and electrically heated mat during 
surgery, stroke, and reperfusion. By using this standardized procedure, we obtained large and 
reproducible infarcted regions involving the temporoparietal cortex and the laterocaudal part of the 
caudate putamen in ischemic animals. Only 1 h of ischemia was employed in the present study because 
findings from our pilot studies (standardization of the model) indicated that in our experimental conditions, 
endovascular occlusion of the middle cerebral artery for 1 h is enough to produce large infarcts in the 
ischemic regions. Infarct volumes obtained with our procedure are very similar to those found with longer 
periods of ischemia [13,51,76]. Several studies have also found large infarct areas using only 1 h of 
transient focal ischemia and have used this model to investigate the effects of different compounds in 
experimental ischemic stroke in the rat [58,67,74,80]. 
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Since nimesulide’s neuroprotection could easily result from drug-induced hypothermia rather than a 
specific pharmacological effect, we strictly monitored rectal temperature and found that nimesulide did 
not modify this physiological variable (data not shown). To allow for better postoperative recovery, we 
chose not to monitor physiological parameters in the present study because additional surgical 
procedures are needed for this monitoring. Nevertheless, we performed a separate experiment to 
investigate the effects of nimesulide on major physiological variables in ischemic rats. Mean arterial blood 
pressure, blood glucose, rectal temperature, hematocrit, blood pH and blood gases (pO2 and pCO2) were 
measured before ischemia, during the occlusion and 30 min after each vehicle or nimesulide (12 mg/kg; 
i.p.) administration. The effects observed with nimesulide in the present study were not related to 
modification of physiological variables since these parameters did not differ between nimesulide-treated 
and vehicle-treated rats (data not shown). These findings are in agreement with our previous results [9], 
suggesting that nimesulide does not significantly change major physiological variables. 
 
2.3. Evaluation of nimesulide’s effects on ischemic damage 
2.3.1. Dose-response experiment  
In order to evaluate the effect of different doses of nimesulide on rat FCI, nimesulide (3, 6 and 12 mg/kg) 
was given to rats by intraperitoneal administration starting immediately after ischemia (n=8-10 animals 
per group). Additional doses were given at 6, 12, 24, 36 and 48 h after stroke. This treatment schedule 
and dosage range were based on the pharmacokinetic profile of nimesulide [71] and on our previous 
experience with this compound in a model of global cerebral ischemia [9,12]. We also performed an 
experiment in which nimesulide was given as a single dose. Control ischemic animals received the 
vehicle of nimesulide (polyvinylpyrrolidone, PVP, n=11). Nimesulide was dissolved in a 2% PVP solution 
[8,9,12]. Neurological evaluation, motor impairment and infarct volumes were determined 3 days later as 
detailed below.  
 
2.3.2. Effects of a single dose of nimesulide 
The effect of a single dose of nimesulide (12 mg/kg; i.p.) given immediately after ischemia was examined 
(n=9). A single injection vehicle-treated group was also included (n=8).  
 
2.3.3. Therapeutic time window assessment 
After investigating the dose-response relationship, we studied the effect of the maximal effective dose of 
nimesulide (12 mg/kg; i.p.) in a situation in which its first administration was delayed for 3 to 24 h after 
ischemia (n= 9-11 animals per group; see Table 1 for detailed treatment schedules). Vehicle-treated 
animals, which underwent transient MCAO, were also included (n= 9-10 animals per group). The 
evaluated variables were measured at 3 days after ischemia because according to results from our pilot 
studies, brain damage is completed by 72 h in our model of transient MCAO (infarct volume at 72 h is not 
significantly different from that measured at 96 h post-stroke, data not shown).  
 
2.4. Neurological evaluation and assessment of functional outcome 
Behavioral tests were performed before MCAO (presurgery) and at 24, 48 and 72 h after MCAO. Each rat 
acted as its own control. Neurological deficits were assessed according to a six-point scale: 0= no 
neurological deficits, 1= failure to extend left forepaw fully, 2= circling to the left, 3= falling to left, 4= no 
spontaneous walking with a depressed level of consciousness, and 5= death [41,44].  
 
Given that the rotarod test is one of the most sensitive to the sensorimotor defects induced by the 
ischemic insult [6,33,72], motor impairment in this study was assessed with the use of the accelerating 
rotarod (Ugo Basile, Varese, Italy, Model 7750). Rats were given 2 training sessions 10 minutes apart 
before surgery. Rats were first habituated to the stationary rod. After habituation they were exposed to the 
rotating rod. The rod was started at 2 rpm and accelerated linearly to 20 rpm within 300 sec. Latency to 
fall off the rotarod was then determined before ischemia (presurgery) and 24, 48 and 72 h after stroke. 
Animals were required to stay on the accelerating rod for a minimum of 30 sec. If they were unable to 
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reach this criterion, the trial was repeated for a maximum of five times. The two best (largest) fall latency 
values a rat could achieve then were averaged and used for data analysis. Rats not falling off within 5 
min were given a maximum score of 300 seconds [7]. A sham-operated group was also included (n=10). 
The investigator performing the neurological evaluation and rotarod test did not know the identity of the 
experimental groups until completion of data analysis. 
 
2.5. Quantification of brain infarct volume 
The method for quantification of infarct volume was performed exactly as previously reported [25,66,78]. 
Briefly, after completing the neurological evaluation and the rotarod test at 3 days after transient FCI, the 
animals were sacrificed under deep anesthesia and brains were removed, frozen and coronally sectioned 
into six 2-mm-thick slices (from rostral to caudal, first to sixth). The brain slices were incubated for 30 min 
in a 2% solution of 2,3,5-triphenyltetrazolium chloride (TTC) (Sigma Chemical Co., Saint Louis, MO, 
USA) at 37 °C and fixed by immersion in a 4% paraformaldehyde solution in phosphate-buffered saline 
pH 7.4. Six TTC-stained brain sections per animal were placed directly on the scanning screen of a color 
flatbed scanner (Hewlett Packard, HP Scanjet 5370 C) within 7 days. Following image acquisition, the 
images were analyzed blindly using a commercial image processing software program (Photoshop, 
version 7.0, Adobe Systems; Mountain View, CA, USA). Measurements were made by manually outlining 
the margins of infarcted areas. The unstained area of the fixed brain section was defined as infarcted. 
Cortical and subcortical uncorrected infarcted areas and total hemispheric areas were calculated 
separately for each coronal slice. Total cortical and striatal uncorrected infarct volumes were calculated 
by multiplying the infarcted area by the slice thickness and summing the volume of the six slices. A 
corrected infarct volume was calculated to compensate for the effect of brain edema. An edema index 
was calculated by dividing the total volume of the hemisphere ipsilateral to MCAO by the total volume of 
the contralateral hemisphere. The actual infarct volume adjusted for edema was calculated by dividing 
the infarct volume by the edema index [48,59,79].  
 
In this study we measured the size of infarction by TTC staining at 3 days after ischemia. In our pilot 
studies, we compared the results of infarcted area (mm2) obtained by TTC staining with those obtained 
using conventional hematoxylin-eosin (H&E) staining. Rats underwent transient FCI (1 h of MCAO) and 
following 3 days of reperfusion, animals were sacrificed, brains were cut into 2 mm slices and stained 
with TTC. The cross-sectional area of the ipsilateral (ischemic) hemisphere and the contralateral 
hemisphere for each brain slice was calculated. H&E-stained sections were also prepared from the brain 
slices (the same slices previously stained with TTC) and analyzed for cross-sectional area as described 
above. Measurements obtained from corresponding TTC-stained brain slices and H&E-stained brain 
sections were directly compared using linear regression and Pearson product moment correlation 
analysis. TTC and H&E defined area measurements were highly correlated (correlation coefficient = 
0.971, P<0.001) (Candelario-Jalil et al., pilot studies), indicating that in our experimental conditions 
measurement of infarct volume using either TTC or H&E staining gives very similar results even after 3 
days of reperfusion. Our results are in line with those previously reported [21,39,54], which show that 
TTC staining could be used to measure infarct volume even 3-4 days after stroke. TTC staining has 
several advantages over other histological techniques (as compared to H&E or Nissl staining techniques, 
TTC staining is cheap, easily to perform and extremely quick). 
 
2.6. Effect of nimesulide on PGE2 elevation in the ischemic brain 
In separate rats, the effect of nimesulide on the elevation in PGE2 concentrations was studied. PGE2 
levels were determined 24 h after induction of stroke, because at this time the concentrations of this 
prostaglandin were dramatically elevated in the ischemic brain (see Fig. 5, Results section). In addition, a 
previous study demonstrated a marked elevation in PGE2 at this time point following transient FCI [51]. 
Nimesulide (12 mg/kg; i.p.; n=9) or vehicle (n=10) were administered at 6, 14 and 22 h after induction of 
ischemia. Rats were sacrificed for PGE2 analysis 2 h after the last nimesulide treatment following a 
similar experimental strategy to that employed by Nogawa et al. [51]. A 4-mm-thick coronal brain slice 
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was cut at the level of the optic chiasm, and the infarcted cortex was quickly dissected out on a chilled 
plate. The corresponding region of the contralateral cortex was also sampled. Tissue was rapidly 
collected, weighed and frozen in liquid nitrogen. A sham-operated group was included in this experiment 
(n=7).  
 
2.7. Prostaglandin E2 (PGE2) Enzyme Immunoassay 
Tissue concentration of PGE2, one of the major cyclooxygenase reaction products in the brain [51], was 
determined using a commercial enzyme immunoassay kit (RPN 222, Amersham Pharmacia Biotech Inc., 
Piscataway, NJ, USA) according to the instructions of the manufacturer. The tissue was homogenized in 
50 mM Tris-HCl (pH 7.4) and extracted with 100 % methanol [57]. After centrifugation, the supernatant 
was diluted with acidified 0.1 M phosphate buffer (pH 4.0; final methanol concentration, 15%) and applied 
to activated octadecylsilyl (ODS)-silica reverse-phase columns (Sep-Pak C18, Waters Associates, 
Milford, MA, USA). The columns were rinsed with 5 mL of distilled water followed by 5 mL of n-hexane, 
and PGE2 was eluted twice with 2 mL of ethyl acetate containing 1% methanol. The ethyl acetate fraction 
was evaporated and resuspended in 1 mL of the buffer provided with the kit. The assay is based on 
competition between unlabeled PGE2 and a fixed amount of peroxidase-labeled PGE2 for a limited 
number of binding sites on a PGE2-specific antibody. Briefly, samples or PGE2 standard were incubated, 
shaken at room temperature for 60 min with specific anti-PGE2 antibody and peroxidase-conjugated 
PGE2 antibody in a goat anti-mouse IgG-precoated 96-well plate. After washing, 3,3´,5,5´-
tetramethylbenzidine substrate was added to the wells and after 30 min the reaction was stopped by 
adding 1 mM sulphuric acid. Subsequently, absorbance was measured at 450 nm. The detection limit of 
this assay is 16 pg/mL.  
 
2.8. Statistical analysis 
Data are presented as means ± S.D. Infarct volumes, infarct areas and PGE2 data were analyzed using t-
test (2 groups) or one way ANOVA with post-hoc Student-Newman-Keuls test (multiple comparison). 
Neurological deficit scores were analyzed by Kruskal-Wallis nonparametric ANOVA followed by the Dunn 
test (multiple comparison) or Mann-Whitney test for analysis of individual differences. Rotarod 
performance was expressed as a percentage of pre-surgery values for each rat and analyzed by ANOVA 
for repeated measures followed by the Student-Newman-Keuls test. Differences were considered 
significant when p<0.05. 
 
 
3. RESULTS 
 
3.1. Effects of different doses of nimesulide on stroke-induced neuronal damage 
Transient occlusion (1 h) of the middle cerebral artery (MCA) by the intraluminal suture method 
consistently produced large infarcts in the territory of the MCA, involving both cortical and subcortical 
structures. Three different clinically-relevant doses of nimesulide were evaluated in this model of transient 
FCI. Table 2 shows the neuroprotective effects of this compound when administered both as a single 
dose and in a long-term treatment paradigm. Nimesulide dose-dependently reduced total and cortical 
infarct volumes and a modest protective effect was also observed with the highest dose (12 mg/kg) in the 
subcortical areas. As compared with a single dose of nimesulide (16 % of infarct reduction), the highest 
dose of nimesulide given as repeated treatments for 2 days reduced by 59 % total (cortical and 
subcortical) infarct volume assessed 3 days after the ischemic stroke. A representative TTC-stained brain 
section of vehicle and nimesulide-treated animals (12 mg/kg, repeated doses) is shown in Fig. 1.  
 
When considered separately, mean cortical infarct volume was decreased by 64 % by treatment with 
nimesulide (12 mg/kg; 6 injections for 2 days post-stroke) compared to vehicle rats (81.5 ± 21.2 and 
227.6 ± 27.4 mm3, respectively; p<0.001). Mean subcortical infarct volume was only slightly reduced by 
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nimesulide at a dose of 12 mg/kg as shown in Table 2. Thus, the significant reduction in total infarction is 
chiefly the result of the potent neuroprotective effect of nimesulide in cortical areas following ischemia. 
 
The rostrocaudal distribution of cortical and subcortical infarct areas in the vehicle and nimesulide 12 
mg/kg groups is depicted in Fig. 2. Cortical infarct areas were significantly smaller (p<0.05) in nimesulide-
treated rats than in the vehicle group at all coronal levels (Fig. 2A). On the contrary of what was found in 
the case of infarcted cerebral cortex, nimesulide only reduced modestly subcortical infarct areas at 
coronal levels 2 and 3 (Fig. 2B).  
 
On the other hand, vehicle-treated control rats exhibited significantly higher neurological deficits scores 
than sham-operated controls (Fig. 3). As compared to vehicle, treatment with nimesulide at the three 
doses examined significantly (p<0.05) improved neurological outcome at 24, 48 and 72 h after stroke, 
although rats in the group treated with nimesulide 12 mg/kg had statistically significant better neurological 
deficit scores than animals treated with the lowest doses at 48 and 72 h after FCI. No significant 
reduction in neurological deficits was observed when nimesulide (12 mg/kg) was given as a single dose 
although a trend towards a better neurological outcome was noticed at 24 h post-stroke (data not shown).  
 
In the accelerating rotarod test, each animal acted as its own control, and performance was compared 
with pre-surgery results (Table 3). Vehicle-treated ischemic rats showed significant impairments in 
performance 24, 48 and 72 h after stroke compared with sham-operated rats. Repeated administrations 
of the three doses of nimesulide similarly protected (p<0.05) against motor impairment seen after stroke 
(Table 3). Treatment with a single dose given immediately after ischemia did not improve performance in 
the rotarod test (Table 3).  
 
3.2. Time window for nimesulide protection in rats subjected to transient focal cerebral ischemia 
 
Given the potent neuroprotection observed with nimesulide at a dose of 12 mg/kg, we decided to select 
this dose for subsequent experiments evaluating the therapeutic window of protection of this COX-2 
inhibitor. When nimesulide treatment was delayed for 3 to 24 h after ischemia, a significant reduction in 
infarct volume was observed 3 days after stroke, although an overall decline of efficacy with post-
treatment time was observed (Table 4). Total infarct volume was reduced by 51%, 42%, 37% and 17% 
when drug administration began 3, 6, 12 or 24 h after stroke, respectively. Similar to what was found in 
the case of immediate administration (Table 2), nimesulide did not confer protection against ischemic 
damage in subcortical areas (Table 4). Thus, the significant reduction in cortical infarction accounts for 
the marked decrease in total infarct volume observed in rats given nimesulide in a delayed therapeutic 
schedule.  
 
Interestingly, nimesulide not only reduced infarction but enhanced functional recovery 3 days after 
ischemia even when its first administration began 24 h after stroke (Fig. 4).  Neurological deficits were 
significantly reduced by post-ischemic treatment with nimesulide (Fig. 4A). Furthermore, latency to 
remain on the accelerating rotarod was compared in ischemic rats treated with either vehicle or with 
nimesulide in the delayed administration paradigm. Nimesulide-treated rats showed significantly 
increased fall latencies compared to those from animals given vehicle alone when treatment was delayed 
for 3-12 h after ischemia (Fig. 4B). However, this protective effect was lost when the first administration is 
delayed until 24 h following the ischemic episode (P=0.183, Student’s t-test, Fig. 4B).  
3.3. Effects of nimesulide on PGE2 accumulation in the ischemic brain 
To determine whether delayed treatment with nimesulide was effective in reducing PGE2 accumulation in 
the ischemic brain, PGE2 levels were measured 24 h after transient stroke in animals treated with 
nimesulide (12 mg/kg; 6 h delayed treatment) or vehicle. There was a dramatic increase (by 244 %) in 
PGE2 levels in the ischemic cortex in those rats treated with the vehicle as compared to the levels of this 
prostaglandin in the contralateral cortex (P<0.001; Fig. 5). Nimesulide completely abolished the post-
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ischemic increases in PGE2 (P<0.001 from vehicle) in the ipsilateral cerebral cortex (stroke side) and the 
PGE2 concentration in the injured cerebral cortex was not different (P>0.05) from that in the intact side 
(contralateral) as shown in Fig. 5.  
 
 
4. DISCUSSION  
Gone are the days when drugs that confer neuroprotection when given before or a short period after 
cerebral ischemia can be considered relevant for therapy of ischemic stroke. Several agents from this 
group have been evaluated clinically and failed. COX-2 inhibition has emerged as a potential therapeutic 
strategy for cerebral ischemia, targeting critical late-occurring pathophysiological events which 
exacerbate the initial brain damage triggered by the ischemic episode.  
 
This study demonstrated that the COX-2 inhibitor nimesulide appreciably reduces cerebral infarction, 
PGE2 accumulation, and also improves functional outcome after transient MCAO in rats. Interestingly, the 
effects of nimesulide on both histological and functional recovery were evident even when the first 
administration was delayed up to 24 h after stroke. Although a previous report demonstrated positive 
effects with a COX-2 selective inhibitor (NS-398) when given after FCI [51], results from the present study 
demonstrate for the first time the wide therapeutic window for nimesulide in a rat stroke model and more 
importantly demonstrated that nimesulide also markedly improved functional recovery. As previously 
suggested [40], pre-clinical studies directed toward demonstrating functional improvement of neurological 
function in addition to reduction of infarct size may improve the predictive value of animal models for 
clinical efficacy with novel neuroprotective agents.  
 
Present results that nimesulide protects neurons when administered several hours after stroke is 
consistent with our previous studies which have found that COX-2 selective inhibitors have a wide 
therapeutic window for protection in global cerebral ischemia [9-12], thus extending our observations to a 
model of transient focal ischemic stroke.  
 
It is important to discuss the finding that nimesulide did not reduce damage to subcortical areas (mainly 
striatum) when administered in a delayed fashion and only slightly diminished infarct volume in striatum 
when given immediately after stroke at the highest dose (Table 2; Fig. 2). The striatum is considered to 
be the core of the ischemic lesion, it lacks collateral circulation and has proved relatively refractory to 
neuroprotection [24]. In addition, results from a previous study [51] indicated that COX-2 protein 
expression is not upregulated in striatum after transient cerebral ischemia, suggesting that COX-2 seems 
not to be an important pathophysiological mediator of ischemic damage in this brain region. This probably 
helps to explain our present results. The mild positive effects seen with the highest dose of nimesulide 
(Table 2; Fig. 2) might be attributable to other pharmacological effects of this compound not related to 
COX-2 inhibition, although further studies are needed to support this notion.  
 
On the other hand, repeated treatments with nimesulide afforded a more remarkable neuroprotection 
than the administration of a single dose given immediately after ischemia (Tables 2 and 3). These 
findings show the importance of a continuous long-term therapeutic regime after focal stroke in clinical 
trials to achieve the maximal beneficial effects of neuroprotection with nimesulide to target the delayed 
progression of tissue damage. 
 
According to our results, the lowest dose of nimesulide (3 mg/kg) reduced neurological deficits and motor 
impairment (Table 3 and Fig. 3) similarly to the highest dose of this COX-2 inhibitor (12 mg/kg), but these 
positive effects were not accompanied by a significant reduction in infarct volume (Table 2). This might 
reflect the fact that unlike ischemic injury to many other tissues, the severity of disability is not predicted 
well by the amount of brain tissue lost. For example, damage to a small area in the medial temporal lobe 
may lead to severe disability, while damage to a greater volume elsewhere had little effect on function 
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[22]. The majority of studies directed toward determining neuroprotective efficacy have used reduction of 
infarct volume as a measure of a drug’s efficacy in animals subjected to focal ischemia. Although it is 
presumed that reduced lesion size will translate to improved functional outcome, a direct correlation is not 
always observed in animals models [32] or in stroke patients [68].   
 
Pharmacological inhibition of COX-2 has been previously shown to reduce N-methyl-D-aspartate-
mediated neuronal cell death both in vitro [29] and in vivo [36]. In addition, recent investigations have 
found a potentiation of excitotoxicity in transgenic mice overexpressing neuronal COX-2 [37] and a 
significant reduction in ischemic brain injury in COX-2-deficient mice [36,62]. 
 
COX-2 expression by itself does not lead to neuronal death since a variety of healthy neuronal 
populations throughout the CNS express COX-2 mRNA and protein under normal conditions [5,77] and 
COX-2 expression can be experimentally induced without causing neuronal death [56]. In the study of 
Planas et al. [56], they found the same level of COX-2 induction in response to both 10 min (mild enough 
not to cause inflammation or cell death) and 1 h of stroke (which leads to brain infarct), suggesting that 
COX-2 would only mediate neuronal injury in the context of an inflammatory response. Results from 
previous studies indicated a close relationship between COX-2 and iNOS in experimental models of FCI 
[49,52]. These two pro-inflammatory enzymes are expressed at the same time and in close proximity in 
penumbral regions [52]. Pharmacological inhibition of iNOS attenuates accumulation of PGE2 in the 
ischemic brain and COX-2 selective inhibitors decrease ischemic injury in wild type mice but not in iNOS 
knockout mice [49]. These results suggest that iNOS and COX-2 may work synergistically to exacerbate 
damage in brain, perhaps through the formation of peroxynitrite and the ensuing oxidative stress.  
 
The production of pro-inflammatory prostanoids is an injurious mechanism associated to the COX-2 
enzymatic activity and this process is associated with the generation of highly reactive oxygen species, 
which have potent deleterious effects on cells [42]. We found that delayed treatment of rats with 
nimesulide completely abolished the marked increase in PGE2 seen in the ischemic cortex 24 h after 
stroke. These results are consistent with the hypothesis that COX-2 reaction products contribute to the 
delayed progression of brain injury following transient FCI.  
 
Several additional mechanisms could account for the neuroprotection conferred by nimesulide in focal 
stroke. The possibility that nimesulide diminished cerebral injury through mechanisms involving reduction 
of oxidative damage, inhibition of pro-inflammatory cytokines production and blockade of apoptotic 
pathways cannot be excluded. Recently, we have found that nimesulide is able to reduce oxidative 
damage following excitotoxic or ischemic brain injury  [8,12]. Furthermore, nimesulide has been proven to 
inhibit TNF-α production [3] and glutamate-mediated apoptotic damage [45]. Further studies are needed 
to elucidate other potential mechanisms apart from COX-2 inhibition which contribute to the 
neuroprotective effects of nimesulide in ischemic stroke.  
 
The inflammatory cascade following cerebral ischemia comprises several mediators (e.g., cytokines, 
chemokines, adhesion molecules, eicosanoids, nitric oxide), which interact among them to produce a 
long-lasting inflammatory reaction observed not only in animal models but in patients with ischemic stroke 
[19,35,60]. Inflammation is an attractive pharmacologic opportunity, considering its rapid initiation and 
progression over many hours/days after stroke and its well-demonstrated contribution to evolution of 
tissue damage [4]. Nevertheless, anti-inflammatory interventions have been shown to interfere with 
nervous regeneration/plasticity and recovery following some types of neuronal injury [17,31], suggesting 
that the potential beneficial effects of inflammation in tissue repair and remodeling need to be considered 
when developing treatment strategies aimed at reducing post-ischemic inflammation.  
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Considering all these previous evidences on the dual role of inflammation following brain injury, further 
work needs to be done in order to investigate the long-term effects of nimesulide in the ischemic brain 
before this compound could be used in the treatment of patients suffering from ischemic stroke.  
 
In summary, the present study has demonstrated a marked neuroprotective effect of nimesulide against 
transient focal ischemic injury at therapeutically relevant doses when administered even 24 h after 
ischemia. Of great importance is the result that nimesulide not only reduced infarct size but also improved 
functional outcome. Our findings hold a therapeutic promise to intervene neuronal injury evolving after 
stroke with the COX-2 inhibitor nimesulide.  
 
 
REFERENCES 
 
[1] K. Abe, Therapeutic potential of neurotrophic factors and neural stem cells against ischemic brain injury, J. Cereb. Blood 
Flow Metab. 20 (2000) 1393-1408. 
[2] G. W. Albers, Expanding the Window for Thrombolytic Therapy in Acute Stroke, Stroke 30 (1999) 2230-2237.  
[3] A. Azab, V. Fraifeld, J. Kaplanski, Nimesulide prevents lipopolysaccharide-induced elevation in plasma tumor necrosis 
factor-alpha in rats, Life Sci. 63 (1998) 323-327.  
[4] F.C. Barone, G.Z. Feuerstein, Inflammatory mediators and stroke: new opportunities for novel therapeutics, J. Cereb. 
Blood Flow Metab. 19 (1999) 819-834. 
[5] C.D. Breder, D. Dewitt, R.P. Kraig, Characterization of inducible cyclooxygenase in rat brain, J. Comp. Neurol. 355 (1995) 
296-315. 
[6] J.K. Callaway, M.J. Knight, D.J. Watkins, P.M. Beart, B. Jarrott, Delayed treatment with AM-36, a novel neuroprotective 
agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats, Stroke 30 
(1999) 2704–2712. 
[7] J.K. Callaway, A.J. Lawrence, B. Jarrott, AM-36, a novel neuroprotective agent, profoundly reduces reactive oxygen 
species formation and dopamine release in the striatum of conscious rats after endothelin-1-induced middle cerebral artery 
occlusion, Neuropharmacology 44 (2003) 787–800.  
[8] E. Candelario-Jalil, H.H. Ajamieh, S. Sam, G. Martínez, O.S. León, Nimesulide limits kainate-induced oxidative damage in 
the rat hippocampus, Eur. J. Pharmacol. 390 (2000) 295-298. 
[9] E. Candelario-Jalil, D. Alvarez, A. González-Falcón, M. García-Cabrera, G. Martínez-Sánchez, N. Merino, A. Giuliani, 
O.S. León, Neuroprotective efficacy of nimesulide against hippocampal neuronal damage following transient forebrain 
ischemia, Eur. J. Pharmacol. 453 (2002) 189-195. 
[10] E. Candelario-Jalil, D. Alvarez, J.M. Castañeda, S.M. Al-Dalain, G. Martínez, N. Merino, O.S. León, The highly selective 
cyclooxygenase-2 inhibitor DFU is neuroprotective when given several hours after transient cerebral ischemia in gerbils, 
Brain Res. 927 (2002) 212-215.  
[11] E. Candelario-Jalil, A. González-Falcón, M. García-Cabrera, D. Alvarez, S.M. Al-Dalain, G. Martínez, O.S. León, J.E. 
Springer, Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and 
neurodegeneration following transient global cerebral ischemia, J. Neurochem. 86 (2003) 545–555.  
[12] E. Candelario-Jalil, D. Alvarez, N. Merino, O.S. León, Delayed treatment with nimesulide reduces measures of oxidative 
stress following global ischemic brain injury in gerbils,  Neurosci. Res. 47 (2003) 245-253.  
[13] P.E. Chabrier, M. Auguet, B. Spinnewyn, S. Auvin, S. Cornet, C. Demerlé-Pallardy, C. Guilmard-Favre, J.G. Marin, B. 
Pignol, V. Gillard-Roubert, C. Roussillot-Charnet, J. Schulz, I. Viossat, D. Bigg, S. Moncada, BN 80933, a dual inhibitor of 
neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective strategy, Proc. Natl. Acad. Sci. USA 96 
(1999) 10824-10829. 
[14] J.A. Clemens, Cerebral ischemia: gene activation, neuronal injury, and the protective role of antioxidants, Free Radic. 
Biol. Med. 28 (2000) 1526-1531. 
[15] Y. Collaço-Moraes, B. Aspey, M. Harrison, J. de Belleroche, Cyclo-oxygenase-2 messenger RNA induction in focal 
cerebral ischemia, J. Cereb. Blood Flow Metab. 16 (1996) 1366-1372.  
[16] L. Cullen, L. Kelly, S.O. Connor, D.J. Fitzgerald, Selective cyclooxygenase-2 inhibition by nimesulide in man, J. 
Pharmacol. Exp. Ther. 287 (1998) 578-582.  
[17] P.K. Dash, S.A. Mach, A.N. Moore, Regional expression and role of cyclooxygenase-2 following experimental traumatic 
brain injury, J. Neurotrauma 17 (2000) 69-81.  
[18] G.J. del Zoppo, Clinical trials in acute stroke: why have they not been successful?, Neurology 51 (1998) S59-S61.  
[19] G. del Zoppo, I. Ginis, J.M. Hallenbeck, C. Iadecola, X. Wang, G.Z. Feuerstein, Inflammation and stroke: putative role for 
cytokines, adhesion molecules and iNOS in brain response to ischemia, Brain Pathol. 10 (2000) 95-112. 
Candelario-Jalil et al. 2004                                               Brain Research Vol. 1007, pp. 98-108 (2004) 
 12
[20] W. Derk, M. Krieger, A. Abou-Chebl, J.C. Andrefsky, C.A. Sila, I. L. Katzan, M.R. Mayberg, A.J. Furlan, Cooling for Acute 
Ischemic Brain Damage (COOL AID): An Open Pilot Study of Induced Hypothermia in Acute Ischemic Stroke, Stroke 32 
(2001) 1847-1854. 
[21] S. Dore, T. Otsuka, T. Mito, N. Sugo, T. Hand, L. Wu, P.D. Hurn, R.J. Traystman, K. Andreasson, Neuronal expression of 
cyclooxygenase-2 increases stroke damage, Ann. Neurol. 54 (2003) 155-162. 
[22] L.L. Dugan, D.W. Choi, Hypoxic-ischemic brain injury and oxidative stress. In: G.J. Siegel, B.W. Agranoff, R.W. Albers, 
S.K. Fisher, M.D. Uhler (Eds.), Basic Neurochemistry: Molecular, Cellular and Medical Aspects. Lippincott-Raven 
Publishers, Philadelphia, 1999, pp. 711-729.  
[23] A.G. Dyker, K.R. Lees, Duration of neuroprotective treatment for ischemic stroke, Stroke 29 (1998) 535-542.   
[24] M. Fisher, J.H. Garcia, Evolving stroke and the ischemic penumbra, Neurology 47 (1996) 884-888.  
[25] A. González-Falcón, E. Candelario-Jalil, M. García-Cabrera, O.S. León, Effects of pyruvate administration on infarct 
volume and neurological deficits following permanent focal cerebral ischemia in rats, Brain Res. 990 (2003) 1-7. 
[26] S.H. Graham, J. Chen, Programmed cell death in cerebral ischemia, J. Cereb. Blood Flow Metab. 21 (2001) 99-109. 
[27] W. Hacke, M. Kaste, C. Fieschi, D. Toni, E. Lesaffre, R. von Kummer, G. Boysen, E. Bluhmki, G. Hoxter, M.H. Mahagne, 
Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European 
Cooperative Acute Stroke Study (ECASS), JAMA 274 (1995) 1017-1025. 
[28] W. Hacke, T. Brott, L. Caplan, D. Meier, C. Fieschi, R. von Kummer, G. Donnan, W.D. Heiss, N.G. Wahlgren, M. 
Spranger, G. Boysen, J.R. Marler, Thrombolysis in acute ischemic stroke: controlled trials and clinical experience, 
Neurology 53 (1999) S3-S14.  
[29] S.J. Hewett, T.F. Uliasz, A.S. Vidwans, J.A. Hewett, Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated 
neuronal cell death in primary cortical cell culture, J. Pharmacol. Exp. Ther. 293 (2000) 417-425. 
[30] S.L. Hickenbottom, J. Grotta, Neuroprotective therapy, Semin. Neurol. 18 (1998) 485-492.  
[31] D.L. Hirschberg, E. Yoles, M. Belkin, M. Schwartz, Inflammation after axonal injury has conflicting consequences for 
recovery of function: rescue of spared axons is impaired but regeneration is supported, J. Neuroimmunol. 50 (1994) 9-16. 
[32] A.J. Hunter, K.B. Mackay, D.C. Rogers, To what extent have functional studies of ischaemia in animals been useful in the 
assessment of potential neuroprotective agents?, Trends Pharmacol. Sci. 19 (1998) 59-66. 
[33] A.J. Hunter, J. Hatcher, D. Virley, P. Nelson, E. Irving, S.J. Hadingham, A.A. Parsons, Functional assessments in mice 
and rats after focal stroke, Neuropharmacology 39 (2000) 806–816.  
[34] C. Iadecola, M. Alexander, Cerebral ischemia and inflammation, Curr. Opin. Neurol. 14 (2001) 89-94.  
[35] C. Iadecola, C. Forster, S. Nogawa, H.B. Clark, M.E. Ross, Cyclooxygenase-2 immunoreactivity in the human brain 
following cerebral ischemia, Acta Neuropathol. 98 (1999) 9-14.  
[36] C. Iadecola, K. Niwa, S. Nogawa, X. Zhao, M. Nagayama, E. Araki, S. Morham, M. Ross, Reduced susceptibility to 
ischemic brain injury and NMDA-mediated neurotoxicity in cyclooxygenase-2-deficient mice, Proc. Natl. Acad. Sci. USA 98 
(2001) 1294-1299. 
[37] K.A. Kelley, L. Ho, D. inger, J. Freire-Moar, C.B. Borelli, P.S. Aisen, G.M. Pasinetti, Potentiation of excitotoxicity in 
transgenic mice overexpressing neuronal cyclooxygenase-2, Am. J. Pathol. 155 (1999) 995-1004. 
[38] J. Koistinaho, S. Koponen, P.H. Chan, Expression of cyclooxygenase-2 mRNA after global ischemia is regulated by 
AMPA receptors and glucocorticoids, Stroke 30 (1999) 1900-1906.  
[39] J.M. Lee, G.J. Zipfel, K.H. Park, Y.Y. He, C.Y. Hsu, D.W. Choi, Zinc translocation accelerates infarction after mild 
transient focal ischemia, Neuroscience 115 (2002) 871-878. 
[40] Q. Li, D. Stephenson, Postischemic administration of basic fibroblast growth factor improves sensorimotor function and 
reduces infarct size following permanent focal cerebral ischemia in the rat, Exp. Neurol. 177 (2002) 531-537.  
[41] E.Z. Longa, P.R. Weinstein, S. Carlson, R. Cummins, Reversible middle cerebral artery occlusion without craniectomy in 
rats, Stroke 20 (1989) 84-91. 
[42] L. Marnett, S. Rowlinson, D. Goodwin, A. Kalgutkar, C. Lanzo, Arachidonic acid oxygenation by COX-1 and COX-2. 
Mechanisms of catalysis and inhibition, J. Biol. Chem. 274 (1999) 22903-22906. 
[43] S. Miettinen, F.R. Fusco, J. Yrjanheikki, R. Keinanen, T. Hirvonen, R. Roivainen, M. Narhi, T. Hokfelt, J. Koistinaho, 
Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic 
acid-receptors and phospholipase A2, Proc. Natl. Acad. Sci. USA 94 (1997) 6500-6505. 
[44] K. Minematsu, L. Li, C.H. Sotak, M.A. Davis, M. Fisher, Reversible focal ischemic injury demonstrated by diffusion-
weighted magnetic resonance imaging in rats, Stroke 23 (1992) 1304-1310. 
[45] M. Mirjany, L. Ho, G.M. Pasinetti, Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated 
excitotoxicity, J. Pharmacol. Exp. Ther. 301 (2002) 494-500. 
[46] M. Modo, P. Rezaie, P. Heuschling, S. Patel, D.K. Male, H. Hodges, Transplantation of neural stem cells in a rat model of 
stroke: assessment of short-term graft survival and acute host immunological response, Brain Res. 958 (2002) 70-82.  
[47] N. J. Mulcahy, J. Ross, N.J. Rothwell, S.A. Loddick, Delayed administration of interleukin-1 receptor antagonist protects 
against transient cerebral ischaemia in the rat, Br. J. Pharmacol. 140 (2003) 471–476.  
[48] N. Nagai, M. de Mol, B. van Hoef, M. Verstreken, M. Collen, Depletion of circulating alpha(2)-antiplasmin by intravenous 
plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization, Blood 97 
(2001) 3086-3092. 
[49] M. Nagayama, K. Niwa, T. Nagayama, M.E. Ross, C. Iadecola, The cyclooxygenase-2 inhibitor NS-398 ameliorates 
ischemic brain injury in wild-type mice but not in mice with deletion of the inducible nitric oxide synthase gene, J. Cereb. 
Blood Flow Metab. 19 (1999) 1213-1219. 
Candelario-Jalil et al. 2004                                               Brain Research Vol. 1007, pp. 98-108 (2004) 
 13
[50] M. Nakayama, K. Uchimura, R.L. Zhu, T. Nagayama, M.E. Rose, R.A. Stetler, P.C. Isakson, J. Chen, S.H. Graham, 
Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia, Proc. Natl. 
Acad. Sci. USA 95 (1998) 10954-10959. 
[51] S. Nogawa, F. Zhang, M.E. Ross, C. Iadecola, Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic 
brain damage, J. Neurosci. 17 (1997) 2746-2755. 
[52] S. Nogawa, C. Forster, F. Zhang, M. Nagayama, M.E. Ross, C. Iadecola, Interaction between inducible nitric oxide 
synthase and cyclooxygenase-2 after cerebral ischemia, Proc. Natl. Acad. Sci. USA 95 (1998) 10966-10971.  
[53] B. Onténiente, C. Couriaud, J. Braudeau, A. Benchoua, C. Guégan, The mechanisms of cell death in focal cerebral 
ischemia highlight neuroprotective perspectives by anti-caspase therapy, Biochem. Pharmacol. 66 (2003) 1643–1649. 
[54] S. Parmentier, G.A. Bohme, D. Lerouet, D. Damour, J.M. Stutzmann, I. Margaill, M. Plotkine, Selective inhibition of 
inducible nitric oxide synthase prevents ischaemic brain injury, Br. J. Pharmacol. 127 (1999) 546-552. 
[55] A.M. Planas, M.A. Soriano, E. Rodríguez-Farré, I. Ferrer, Induction of cyclooxygenase-2 mRNA and protein following 
transient focal ischemia in the rat brain, Neurosci. Lett. 200 (1995) 187-190. 
[56] A.M. Planas, M.A. Soriano, C. Justicia, E. Rodríguez-Farré, Induction of cyclooxygenase-2 in the rat brain after a mild 
episode of focal ischemia without tissue inflammation or neural cell damage, Neurosci Lett. 275 (1999) 141-144.  
[57] W.S. Powell, Rapid extraction of arachidonic acid metabolites from biological samples using octadecylsilyl silica. In: 
Lands, W.E.M., Smith, W.L., (Eds), Methods in Enzymology. Academic Press, Orlando, 1982, pp. 466-477. 
[58] V.L.R. Rao, A. Dogan, K.G. Todd, K.K. Bowen, B.T. Kim, J.D. Rothstein, R.J. Dempsey, Antisense knockdown of the glial 
glutamate transporter GLT-1, but not the neuronal glutamate transporter EAAC1, exacerbates transient focal cerebral 
ischemia-induced neuronal damage in rat brain, J. Neurosci. 21 (2001) 1876-1883.  
[59] D. Reglodi, A. Somogyvari-Vigh, S. Vigh, T. Kozicz, A. Arimura, Delayed systemic administration of PACAP38 is 
neuroprotective in transient middle cerebral artery occlusion in the rat, Stroke 31 (2000) 1411-1417. 
[60] T. Sairanen, A. Ristimaki, A. Paetau, P.J. Lindsberg, Cyclooxygenase-2 is induced globally in infarcted human brain, Ann. 
Neurol. 43 (1998) 738-747. 
[61] O. Sanz, A. Estrada, I. Ferrer, A.M. Planas, Differential cellular distribution and dynamics of HSP70, cyclooxygenase-2, 
and c-Fos in the rat brain after transient focal ischemia or kainic acid, Neuroscience 80 (1997) 221-232.  
[62] T. Sasaki, K. Kitagawa, K. Yamagata, T. Takemiya, S. Tanaka, E. Omura-Matsuoka, S. Sugiura, M. Matsumoto, M. Hori, 
Amelioration of hippocampal neuronal damage after transient forebrain ischemia in cyclooxygenase-2-deficient mice, J. 
Cereb. Blood Flow Metab. 24 (2004) 107–113. 
[63] S.I. Savitz, D.M. Rosenbaum, J.H. Dinsmore, L.R. Wechsler, L.R. Caplan LR, Cell transplantation for stroke, Ann. Neurol. 
52 (2002) 266-275. 
[64] R. Schmid-Elsaesser, E. Hungerhuber, S. Zausinger, A. Baethmann, H. J. Reulen, Neuroprotective efficacy of 
combination therapy with two different antioxidants in rats subjected to transient focal ischemia, Brain Res. 816 (1999) 471-
479.  
[65] S. Schwab, S. Schwarz, M. Spranger, E. Keller, M. Bertram, W. Hacke, Moderate hypothermia in the treatment of patients 
with severe middle cerebral artery infarction, Stroke 29 (1998) 2461-2466.  
[66] A. Shuaib, C.X. Wang, T. Yang, R. Noor, Effects of nonpeptide V(1) vasopressin receptor antagonist SR-49059 on 
infarction volume and recovery of function in a focal embolic stroke model, Stroke 33 (2002) 3033-3037. 
[67] A.L. Sirén, M. Fratelli, M. Brines, C. Goemans, S. Casagrande, P. Lewczuk, S. Keenan, C. Gleiter, C. Pasquali, A. 
Capobianco, T. Mennini, R. Heulmann, A. Cerami, H. Ehrenreich, P. Ghezzi, Erythropoietin prevents neuronal apoptosis 
after cerebral ischemia and metabolic stress, Proc. Natl. Acad. Sci. USA 98 (2001) 4044-4049. 
[68] Stroke Therapy Academy Industry Roundtable (STAIR II), Recommendation for clinical trial evaluation of acute stroke 
therapies, Stroke 32 (2001) 1598-1606. 
[69] Y. Taniguchi, K. Yokoyama, K. Noda, Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide, 
Eur. J. Pharmacol. 330 (1997) 221-229. 
[70] The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, Tissue plasminogen activator for 
acute ischemic stroke, New England J. Med. 333 (1995) 1581-1587.  
[71] P.L. Toutain, C.C. Cester, T. Haak, S. Metge, Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by 
nimesulide in the dog, J. Vet. Pharmacol. Ther. 24 (2001) 35-42. 
[72] M. van Lookeren Campagne, H. Thibodeaux, N. Bruggen, B. Cairns, R. Gerlai, J.T. Palmer, S.P. Williams, D.G. Lowe, 
Evidence for a protective role of metallothionein-1 in focal cerebral ischemia, Proc. Natl. Acad. Sci. USA, 96 (1999) 12870–
12875.  
[73] J. Vaughan, N. Delanty, Neuroprotective properties of statins in cerebral ischemia and stroke, Stroke 30 (1999) 1969-
1973. 
[74] J. Wang, X. Yang, C.V. Camporesi, Z. Yang, G. Bosco, C. Chen, E.M. Camporesi, Propofol reduces infarct size and 
striatal dopamine accumulation following transient middle cerebral artery occlusion: a microdialysis study, Eur. J. 
Pharmacol. 452 (2002) 303-308. 
[75] J.H. Weiss, S.L. Sensi, J.Y. Koh, Zn2+: a novel ionic mediator of neural injury in brain disease, Trends Pharmacol. Sci. 21 
(2000) 395-401.  
[76] A.J. Williams, F.C. Tortella, Neuroprotective effects of the sodium channel blocker RS100642 and attenuation of 
ischemia-induced brain seizures in the rat, Brain Res. 932 (2002) 45-55.   
[77] K. Yamagata, K.I. Andreasson, P.F. Worley, Expression of a mitogen-inducible cyclooxygenase in brain neurons, 
regulation by synaptic activity and glucocorticoids, Neuron 11 (1993) 371-386. 
Candelario-Jalil et al. 2004                                               Brain Research Vol. 1007, pp. 98-108 (2004) 
 14
[78] Y. Yang, A. Shuaib, Q. Li, Quantification of infarct size on focal cerebral ischemia model of rats using a simple and 
economical method, J. Neurosci. Meth. 84 (1998) 9-16. 
[79] Y. Yang, Q. Li, H. Miyashita, W. Howlett, M. Siddiqui, A. Shuaib, Usefulness of postischemic thrombolysis with or without 
neuroprotection in a focal embolic model of cerebral ischemia, J. Neurosurg. 92 (2000) 841-847.  
[80] M.A. Yenari, S.L. Fink, G.H. Sun, L.K. Chang, M.K. Patel, D.M. Kunis, D. Onley, D.Y. Ho, R.M. Sapolsky, G.K. Steinberg, 
Gene therapy with HSP72 is neuroprotective in rat models of stroke and epilepsy, Ann. Neurol. 44 (1998) 584-591. 
[81] M.A. Yenari, H. Zhao, R.G. Giffard, R.A. Sobel, R.M. Sapolsky, G.K. Steinberg, Gene therapy and hypothermia for stroke 
treatment, Ann. NY Acad. Sci. 993 (2003) 54-81. 
 
TABLE 1 
 
Treatment schedules to investigate the therapeutic window of nimesulide protection in 
focal ischemic stroke.  
Treatment Post-ischemic time at which 
rats received the first treatment
Additional treatments 
(hours after stroke) 
3 h 9, 15, 27, 39 and 51 h 
6 h 12, 18, 30, 42 and 54 h 
12 h 18, 24, 36, 48 and 60 h 
Vehicle (n= 9-10) or 
Nimesulide 12 mg/kg; i.p 
(n=9-11) 
24 h 30, 36, 48 and 60 h 
 
TABLE 2  
Dose-response effect of nimesulide in a transient model of focal cerebral ischemia and 
different effects of a long-term treatment paradigm versus a single dose.  
Treatment Total infarct volume 
(mm3) 
Cortical infarct volume 
(mm3) 
Subcortical infarct 
volume (mm3) 
Repeated doses    
Vehicle (n=11) 289.7 ± 39.8 227.6 ± 27.4 58.3 ± 19.5 
Nimesulide 3 mg/kg (n=9) 255.2 ± 40.9 207.3 ± 22.2 54.5 ± 12.8 
Nimesulide 6 mg/kg (n=8) 221.4 ± 34.5 * 174.7 ± 19.3 * 49.2 ± 16.4 
Nimesulide 12 mg/kg (n=10) 119.3 ± 37.8 ** , ‡ 81.5 ± 21.2 ** , ‡ 41.8 ± 18.6 &  
Single dose    
Vehicle, single dose (n=8) 295.2 ± 42.9 235.9 ± 30.4 62.3 ± 20.1 
Nimesulide 12 mg/kg, single 
dose (n=9) 
247.5 ± 41.2 † 194.3 ± 17.3 †   51.1 ± 17.5 
 
Data are mean ± S.D. * P<0.01 compared to vehicle. ** P<0.001 compared to vehicle. ‡ P<0.05 compared to 
nimesulide 6 mg/kg.  †p<0.05 compared to vehicle (single dose). ANOVA followed by Student-Newman-
Keuls post-hoc test. & P<0.05 compared to vehicle (Student t-test). 
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TABLE 3 
Effects of different doses of nimesulide on rotarod performance after middle cerebral 
artery occlusion in rats.  
 Rotarod Performance (% of Pre-surgery values)  
Treatment 24 h 48 h 72 h 
Repeated treatments     
Sham (n=10) 121 ± 16 139 ± 21 128 ± 26 
Vehicle (n=11) 58 ± 17 51 ± 20 41 ± 19 
Nimesulide 3 mg/kg (n=9) 81 ± 25 * 87 ± 12 * 76 ± 21 * 
Nimesulide 6 mg/kg (n=8) 86 ± 23 * 92 ±15 * 85 ± 16 * 
Nimesulide 12 mg/kg (n=10) 87 ± 13 * 89 ± 14 * 91 ± 18 * 
Single dose    
Vehicle, single dose (n=8) 52 ± 26  40 ± 18  43 ± 22 
Nimesulide 12 mg/kg, single 
dose (n=9) 
64 ± 15  59 ± 21  50 ± 28  
 
Data are mean ± S.D. for rotarod performance expressed as a percentage of pre-surgery performance for 
each individual rat. * P<0.05 compared with vehicle at the indicated time. ANOVA followed by Student-
Newman-Keuls post-hoc test.  
   
TABLE 4 
Effects of nimesulide (12 mg/kg; i.p.) or vehicle at different times of administration after 
transient focal cerebral ischemia on total, cortical and subcortical infarct volumes.  
 
Infarct volume (mm3)  
Total Cortical Subcortical 
Time after 
stroke (h) Vehicle Nimesulide Vehicle Nimesulide Vehicle Nimesulide 
3 295.7 ± 46.4 
(n=9)  
143.4 ± 37.6 
** (n=10) 
237.3 ± 31.2 
(n=9)  
93.3 ± 27.5 
** (n=10) 
55.3 ± 18.5 
(n=9)  
48.2 ± 21.8   
(n=10) 
6 280.9 ± 31.8 
(n=10) 
162.6 ± 42.3 
** (n=10) 
222.8 ± 21.8 
(n=10) 
107.7 ± 20.2 
** (n=10) 
60.2 ± 20.4 
(n=10) 
57.2 ± 15.3 
(n=10) 
12 299.1 ± 39.4 
(n=10) 
188.3 ± 44.8 
** (n=11) 
241.7 ± 29.1 
(n=10) 
130.9 ± 24.3 
** (n=11) 
52.9 ± 19.4 
(n=10) 
61.2 ± 17.5 
(n=11) 
24 290.5 ± 45.2 
(n=9) 
240.2 ± 39.5 
* (n=9) 
246.5 ± 39.2 
(n=9) 
189.1 ± 28.7 
** (n=9) 
47.2 ± 15.2 
(n=9) 
55.1 ± 19.8  
(n=9) 
 
Values are volume of infarction (mean ± S.D.), expressed in cubic millimeters. *P<0.05 and **P<0.01 
compared with vehicle control group (Student’s t-test). 
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Fig. 1. Representative TTC-stained section of vehicle and 
nimesulide-treated animals (12 mg/kg; i.p.; repeated doses 
starting immediately after stroke). Bar= 1 cm. 
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Fig. 2. Rostrocaudal distribution of areas of cortical (A) and subcortical (B) infarction at 
six coronal levels in nimesulide-treated (12 mg/kg; i.p.; repeated doses starting 
immediately after stroke) and vehicle-treated rats assessed 3 days after 1 h of 
transient focal cerebral ischemia. *P<0.05 compared to vehicle.  
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 Fig. 3. Neurological deficit score 24, 48, and 72 hours after 
ischemia in sham-operated control group, ischemic vehicle-treated 
rats and after administration of different doses of nimesulide 
(repeated treatments for 2 days after stroke). *P<0.05 and 
**P<0.01 compared with vehicle.   
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Fig. 4. Effect of delayed administration of nimesulide (12 mg/kg; i.p.) on neurological 
deficit score (A) and rotarod performance (B) after transient middle cerebral artery 
occlusion in male Sprague-Dawley rats. Vehicle or nimesulide was administered 3, 6, 
12 or 24 h after 1 h of focal ischemia. *P<0.05 and **P<0.01 compared to vehicle. 
The number in parentheses shows the number of rats used per group. 
 
 
 
 
 
 
Candelario-Jalil et al. 2004                                               Brain Research Vol. 1007, pp. 98-108 (2004) 
 20
 
0
5
10
15
20
25
30
 
Contralateral 
Stroke 
PG
E 2
 (n
g/
g 
w
et
 ti
ss
ue
) 
** 
§ 
Sham 
(n=7) 
Vehicle 
(n=10) 
Nimesulide 
(n=9) 
 Fig. 5. Effect of the COX-2 inhibitor nimesulide (12 mg/kg; i.p.; starting 6 h after 
ischemia) on postischemic increase in prostaglandin E2 (PGE2) in the ischemic 
cerebral cortex after 24 h of transient (1 h) focal stroke. Nimesulide completely 
abolished PGE2 accumulation in the ischemic brain. **P<0.001 from vehicle 
contralateral. §P<0.001 from vehicle stroke.  
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